Bimatoprost periocular ring - Allergan

Drug Profile

Bimatoprost periocular ring - Allergan

Alternative Names: Bimatoprost HELIOS™ insert; Bimatoprost peri-ocular insert; Bimatoprost peri-ocular ring; Bimatoprost sustained release ocular insert; Vision-5-product

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ForSight VISION5
  • Developer Allergan
  • Class Amides; Amino alcohols; Antiglaucomas; Lipids; Morpholines; Propanolamines; Prostaglandins; Small molecules; Thiadiazoles
  • Mechanism of Action Prostaglandin F2alpha receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Glaucoma; Ocular hypertension

Most Recent Events

  • 04 May 2017 Phase-II development for Glaucoma and Ocular hypertension is ongoing in USA (Ophthalmic) (Allergan pipeline, May 2017)
  • 01 Aug 2016 ForSight Vision5 completes a phase I/II extension trial for Glaucoma and Ocular hypertension in USA (NCT02537015)
  • 01 Jan 2016 ForSight VISION5 completes the phase I/II extension trial in Glaucoma and Ocular hypertension in USA (NCT02143843)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top